Article Text

Download PDFPDF
Robot-Assisted Radical Hysterectomy in Cervical Carcinoma: The Belgian Experience
  1. An Segaert, MD*,
  2. Koen Traen, MD,
  3. Philippe Van Trappen, MD,
  4. Frederik Peeters, MD§,
  5. Karin Leunen, MD, PhD*,
  6. Frédéric Goffin, MD, PhD and
  7. Ignace Vergote, MD, PhD*
  1. *Division of Gynaecological Oncology, Department of Obstetrics and Gynecology, Leuven Cancer Institute, KU Leuven, Leuven;
  2. Department of Gynecology, OLV Aalst, Aalst;
  3. Department of Gynecology, AZ Sint-Jan, Bruges;
  4. §Department of Gynecology, AZ Klina, Brasschaat; and
  5. Division of Gynecological Oncology, Department of Obstetrics and Gynecology, CHU de Liège, site CHR de la Citadelle, Liège, Belgium.
  1. Address correspondence and reprint requests to Ignace Vergote, MD, PhD, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Leuven Cancer Institute, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. E-mail: ignace.vergote{at}


Objective The purpose of this study was to report the experience and oncological outcome of robot-assisted radical hysterectomies (RRHs) for cervical cancer performed in Belgium.

Methods Patients undergoing RRH for cervical cancer (n = 109) were prospectively collected between July 2007 and April 2014 in the 5 Belgian centers performing RRH for cervical cancer.

Results The median age of the patients was 46 years (range, 31–80 years). Histological types included squamous cell carcinoma in 61 patients, adenocarcinoma in 22 patients, adenosquamous in 8 patients, endometrioid carcinoma in 2 patients, and other types (n = 16). The International Federation of Gynecology and Obstetrics stage distribution was IA (n = 9), stage IB1 (n = 71), stage IB2 (n = 4), stage II (n = 24), and unknown (n = 1). Twenty-four patients received adjuvant therapy, 17 patients underwent radiochemotherapy, and 7 underwent adjuvant radiation. Eighteen patients relapsed, and 5 died of disease. The median follow-up was 27.5 months (range, 3–82 months). The 2- and 5-year overall survivals were 96% and 89%, respectively. The 2- and 5-year disease-free survivals (DFSs) were 88% and 72%, respectively. The 2-year DFS per stage was 100% for IA, 88% for IB1, 100% for IB2, and 83% for II. The 5-year DFS per stage was 100% for stage IA and 75% for IB1. The complications were as expected for radical hysterectomy.

Conclusions This series confirms the feasibility and safety of RRH not only in cervical cancer stage IA to IB1, but also after neoadjuvant chemotherapy in stage IB2 to IIB.

  • Robot-assisted management
  • Cervical cancer
  • Radical hysterectomy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.